drugset
drugset / Trial / NCT06321601

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

NCT06321601 ↗

Phase 3 Active not recruiting 19 enrolled Amgen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.

Timeline

Start
2024-10-22
Primary completion
2027-07-18
Completion
2027-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Avacopan Small molecule — Oral

Indications

vasculitis